combination with collagen crosslinking for keratoconus

Purpose: To compare visual outcomes, corneal astigmatism, and keratometric readings in patients with progressive keratoconus undergoing intrastromal corneal ring implantation (ICRSI) only and in combination with ultraviolet A riboflavin mediated corneal collagen crosslinking (CXL).Methods: In this retrospective comparative study, there were 2 groups of keratoconus patients. Group 1 consisted of only ICRSI patients. Group 2 consisted of combined ICRSI-CXL patients. Preoperative and postoperative uncorrected distance visual acuity (UCDVA) and best-corrected distance visual acuity (BCDVA), spherical error, cylindrical error; and mean keratometty were compared.Results: The study evaluated 166 eyes of 121 patients with a mean age of 24.74 years. The UCDVA improved from 0.24 to 0.37 in group 1 and from 0.24 to 0.42 in group 2 at the last visit. The BCDVA improved from 0.34 to 0.62 in group 1 and from 0.31 to 0.67 in group 2. Spherical error decreased from -5.05 D to -1.65 D in group 1 and from -4.82 D to -1.52 D in group 2. Cylindrical error decreased from -6.06 D to -3.47 D in group 1 and from -5.66 D to -3.20 D in group 2. Mean keratometry values decreased from 51.89 D to 47.96 D in group 1 and from 50.89 D to 46.91 D in group 2. p Value was >0.05 in group comparisons. Ring explantation due to corneal melting was applied in 3 eyes.Conclusions: Both combined ICRSI-CXL and ICRSI-only groups experienced favorable outcomes, without statistical difference in any studied effect of both treatment strategies

Development of a novel experimental In vitro model of isothiocyanate-induced apoptosis in human malignant melanoma cells

Background: Isothiocyanates are constituents of cruciferous vegetables which have been associated with reduced cancer risk partially through their ability to induce apoptosis in malignant cells including melanoma. Materials and Methods: We have utilized human malignant melanoma (A375), epidermoid carcinoma (A431) and immortalized keratinocyte (HaCaT) cells exposed to various isothiocyanates, under different experimental conditions. Results: An experimental in vitro model utilizing low isothiocyanate concentrations (0.1-5 μM for 48 h with all treatments being refreshed after 24h) was shown to be (i) most efficient in exerting an anti-cancer effect when compared to higher concentrations (5-100 μM for 24 or 48 h added as a single bolus) and (ii) specific to A375 cells while A431 and HaCaT cells remained unaffected. Such effect involved the activation of several caspases including (iii) initiator caspases 8, 9, 4 (indicating the involvement of intrinsic, extrinsic and endoplasmic reticulum-based pathways) and (iv) effector caspases 3, 7 and 6. Conclusion: Utilization of low isothiocyanate concentrations (under the conditions described herein) exerts an anti-cancer effect specific to human malignant melanoma cells thus providing a therapeutic basis for their utilization in management of the disease

Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis

PURPOSE. Parafoveal telangiectasis (PT) is a developmental or acquired microvascular abnormality of the macula. Leakage of the abnormal parafoveal capillaries leads to macular edema with subsequent decrease in visual acuity. Intravitreal triamcinolone acetonide is recently widely used in the management of intraocular proliferative, edematous, and neovascular diseases

Refractive lenticule extraction (ReLEx) through a small incision (SMILE) for correction of myopia and myopic astigmatism: current perspectives

Alper Ağca,1 Ahmet Demirok,2 Yusuf Yıldırım,1 Ali Demircan,1 Dilek Yaşa,1 Ceren Yeşilkaya,1 İrfan Perente,1 Muhittin Taşkapılı1 1Beyoğlu Eye Research and Training Hospital, 2Department of Ophthalmology, Istanbul Medeniyet University, Istanbul, Turkey Abstract: Small-incision lenticule extraction (SMILE) is an alternative to laser-assisted in situ keratomileusis (LASIK) and photorefractive keratectomy (PRK) for the correction of myopia and myopic astigmatism. SMILE can be performed for the treatment of myopia ≤-12 D and astigmatism ≤5 D. The technology is currently only available in the VisuMax femtosecond laser platform. It offers several advantages over LASIK and PRK; however, hyperopia treatment, topography-guided treatment, and cyclotorsion control are not available in the current platform. The working principles, potential advantages, and disadvantages are discussed in this review. Keywords: SMILE, small-incision lenticule extraction, femtosecond laser, laser in situ keratomileusis, corneal biomechanic

Radial keratotomy for the optical rehabilitation of mild to moderate keratoconus: More than 5 years' experience

PURPOSE. To present the authors' long-term experience of radial keratotomy (RK) for the optical rehabilitation of patients with mild to moderate keratoconus-central corneal thickness of greater than 400 mu m and without apical scarring

Ranibizumab for the treatment of degenerative ocular conditions

Magdalini Triantafylla,1 Horace F Massa,2 Doukas Dardabounis,1 Zisis Gatzioufas,2 Vassilios Kozobolis,1 Konstantinos Ioannakis,1 Irfan Perente,1,3 Georgios D Panos1,21Department of Ophthalmology, University General Hospital of Alexandroupolis, School of Medicine, University of Thrace, Alexandroupolis, Greece; 2Department of Ophthalmology, Geneva University Hospitals, Faculty of Medicine, University of Geneva, Switzerland; 3Beyoglou Eye Research and Teaching Hospital, Istanbul University, Istanbul, TurkeyAbstract: Degenerative ocular conditions, such as age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, and myopic degeneration, have become a major public health problem and a leading cause of blindness in developed countries. Anti-vascular endothelial growth factor (VEGF) drugs seem to be an effective and safe treatment for these conditions. Ranibizumab, a humanized monoclonal antibody antigen-binding fragment, which inhibits all biologically active isoforms of VEGF-A, is still the gold standard treatment for the majority of these pathological entities. In this review, we present the results of the most important clinical trials concerning the efficacy and safety of ranibizumab for the treatment of degenerative ocular conditions.Keywords: age-related macular degeneration, diabetic macular edema, retinal vein occlusion, anti-VEGF, safety, efficacy, quality of lif

Remove, rotate, and reimplant: a novel technique for the management of exposed porous anophthalmic implants in eviscerated patients

Purpose To describe and to evaluate a new and relatively easy technique for porous implant exposure repair

Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy

Zeynep Alkin,1 Irfan Perente,1 Abdullah Ozkaya,1 Dilek Alp,1 Alper Agca,1 Ebru Demet Aygit,1 Selcuk Korkmaz,2 Ahmet Taylan Yazici,1 Ahmet Demirok1 1Beyoglu Eye Training and Research Hospital, Istanbul, Turkey; 2Hacettepe University Faculty of Science, Department of Statistics, Ankara, Turkey Purpose: To compare the efficacy of low-fluence photodynamic therapy (PDT) and PDT with half-dose verteporfin in chronic central serous chorioretinopathy (CSC). Patients and methods: The medical records of 64 eyes from 60 patients with chronic CSC were retrospectively reviewed; 36 eyes received low-fluence PDT (25 J/cm2) and 28 eyes received half-dose verteporfin PDT (3 mg/m2). The primary outcome measure was the proportion of eyes with complete resolution of subretinal fluid. Secondary outcome measures were the changes in best corrected visual acuity (BCVA) and central foveal thickness, and the proportion of eyes that showed an increase of ≥5 letters in BCVA at the last visit. Results: The mean follow-up period was12.5±4.3 months and 13.1±4 months in the low-fluence group and half-dose group, respectively (P=0.568). Thirty-three eyes (91.6%) in the low-fluence group and 26 eyes (92.8%) in the half-dose verteporfin group showed complete resolution of subretinal fluid (P=0.703). BCVA increased by a mean of 7.4 letters and 4.8 letters in the low-fluence group and half-dose group, respectively (P=0.336). Seventeen eyes (52.8%) in the low-fluence group and 14 eyes (50%) in the half-dose group experienced a gain of ≥5 letters in BCVA (P=0.825). In the low-fluence and half-dose verteporfin group, the mean baseline central foveal thickness was 351±90 µm and 341±96 µm, and significantly decreased to 188±61 µm and 181±47 µm, respectively (P<0.01). Conclusion: Both treatments resulted in complete subretinal fluid resolution in most of the eyes, with significantly better visual acuity outcomes compared to baseline at the last visit. Keywords: low-fluence, half-dose verteporfin, photodynamic therapy, central serous chorioretinopath